Differential Expression of MicroRNAs in Calcific Aortic Stenosis

Xu, Haixia; Wang, Yan; Zheng, Duo; Wang, Teng; Pan, Min; Shi, Jiahai; Zhu, Jianhua; Li, Xiaofei

doi:10.7754/clin.lab.2017.170108

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our hub genes and cross-linked miRNAs results in Table 2 also demonstrated that miRNA-199b-5p may directly target ACTN2 and ANK2 genes which are both suppressed in CAVS, suggesting the effects of these molecules on the pathogenesis of aortic stenosis. In addition, miRNA-374b [49], miRNA-340 [50] and miRNA-203 [51] have also been reported to be abnormally expressed in aortic stenosis patients, which can be used as a diagnostic/ prognostic biomarker of CAVS in the future. However, during the process of the disease, genetic alteration may occur secondary to some pathological changes.…”

Section: Discussionmentioning

confidence: 99%

miRNA-mRNA crosstalk in myocardial ischemia induced by calcified aortic valve stenosis

Duan

Cao

Tang

et al. 2019

Aging

View full text Add to dashboard Cite

Aortic valve stenosis is the most common cause of morbidity and mortality in valvular heart disease in aged people. Both microRNA (miRNA) and mRNA are potential targets for the diagnosis and therapeutic intervention of myocardial ischemia induced by calcified aortic valve stenosis (CAVS), with unclear mechanisms. Here, 3 gene expression profiles of 47 male participants were applied to generate shared differentially expressed genes (DEGs) with significant major biological functions. Moreover, 20 hub genes were generated by a Weighted Genes Co-Expression Network Analysis (WGCNA) and were cross-linked to miRNA based on miRanda/miRwalk2 databases. Integrated miRNA/mRNA analysis identified several novel miRNAs and targeted genes as diagnostic/prognostic biomarkers or therapeutic targets in CAVS patients. In addition, the clinical data suggested that myocardial hypertrophy and myocardial ischemia in CAVS patients are likely associated with hub genes and the upstream regulatory miRNAs. Together, our data provide evidence that miRNAs and their targeted genes play an important role in the pathogenesis of myocardial hypertrophy and ischemia in patients with CAVS.

show abstract

Section: Discussionmentioning

confidence: 99%

miRNA-mRNA crosstalk in myocardial ischemia induced by calcified aortic valve stenosis

Duan

Cao

Tang

et al. 2019

Aging

View full text Add to dashboard Cite

show abstract

“…In addition to their potential as therapeutic targets, those miRNAs that have been found to be functionally involved in BAV disease and morphology [ 142 ] should be further screened in BAV aortopathy (and controls) tissue and plasma/serum samples (including their extracellular vesicles components) to gain evidence of their potential as diagnostic and prognostic biomarkers.…”

Section: The Role Of Micrornasmentioning

confidence: 99%

Enlightening the Association between Bicuspid Aortic Valve and Aortopathy

Sophocleous

Milano

Pontecorboli

et al. 2018

JCDD

View full text Add to dashboard Cite

Bicuspid aortic valve (BAV) patients have an increased incidence of developing aortic dilation. Despite its importance, the pathogenesis of aortopathy in BAV is still largely undetermined. Nowadays, intense focus falls both on BAV morphology and progression of valvular dysfunction and on the development of aortic dilation. However, less is known about the relationship between aortic valve morphology and aortic dilation. A better understanding of the molecular pathways involved in the homeostasis of the aortic wall, including the extracellular matrix, the plasticity of the vascular smooth cells, TGFβ signaling, and epigenetic dysregulation, is key to enlighten the mechanisms underpinning BAV-aortopathy development and progression. To date, there are two main theories on this subject, i.e., the genetic and the hemodynamic theory, with an ongoing debate over the pathogenesis of BAV-aortopathy. Furthermore, the lack of early detection biomarkers leads to challenges in the management of patients affected by BAV-aortopathy. Here, we critically review the current knowledge on the driving mechanisms of BAV-aortopathy together with the current clinical management and lack of available biomarkers allowing for early detection and better treatment optimization.

show abstract

“…Later, in a comparison between valves of healthy controls and patients with calcific aortic stenosis, miR-214 was increased in CAVD patients and osteocalcin, osteopontin, Runx2, and osterix were identified and validated as its targets. 41 Furthermore, in excised AVs from patients with CAVD, increased miR-214 expression was found to play a role in suppressing the apoptosis repressor with caspase recruitment domain ARC. 42 In addition, it was demonstrated that miR-214 stimulates the formation of calcific nodules in haVICs in vitro via the MyD88/NF-κB inflammatory pathway.…”

Section: Resultsmentioning

confidence: 98%

Controlled delivery of gold nanoparticle-coupled miRNA therapeuticsviaan injectable self-healing hydrogel

et al. 2021

View full text Add to dashboard Cite

show abstract

Differential Expression of MicroRNAs in Calcific Aortic Stenosis

Abstract: MiR-26a, miR-939, and miR-374b* expression was decreased and miR-214 was increased in the calcified aortic valves of CAS patients. miR-214 may promote aortic valve calcification by repressing TWIST1 expression.

Cited by 9 publications

References 0 publications

miRNA-mRNA crosstalk in myocardial ischemia induced by calcified aortic valve stenosis

miRNA-mRNA crosstalk in myocardial ischemia induced by calcified aortic valve stenosis

Enlightening the Association between Bicuspid Aortic Valve and Aortopathy

Controlled delivery of gold nanoparticle-coupled miRNA therapeuticsviaan injectable self-healing hydrogel

Contact Info

Product

Resources

About